» Articles » PMID: 390084

Human Immune Response to Immunization with a Structurally Defined Polypeptide Fragment of Streptococcal M Protein

Overview
Journal J Exp Med
Date 1979 Oct 1
PMID 390084
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We tested the ability of pepsin-extracted, highly purified M protein to induce type-specific immunity in experimental animals and humans. M protein was prepared from limited peptic digests of whole group A type 24 streptococci and was purified to chemical homogeneity as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, quantitative amino acid analysis, and Edman degradation. For vaccination, the lyophilized M24 protein preparation (pep M24) was precipitated in aluminum hydroxide. When injected into laboratory animals, alum-precipitated pep M24 produced type-specific protective antibodies and was free of non-type-specific immunoreactivity. In man, skin tests with 1-microgram doses of pep M24 were negative in all 37 adults tested. 12 adult human volunteers received two-four subcutaneous injections of 100-200 micrograms of alum-precipitated pep M24 at intervals of at least 2 wk. The immune response to pep M24 was measured by a variety of assays designed to detect (a) type-specific humoral antibodies (opsonophagocytic, long chain, and mouse protection tests); (b) total humoral antibodies (complement fixation and enzyme-linked immunosorbent assay); (c) cellular immunity (skin tests); and (d) heart cross-reactive antibodies (immunofluorescence). Type-specific opsonic antibodies developed in 10 of the 12 vaccinees, and positive delayed-type skin tests developed in 11. Immune sera from two of the vaccinees were effective in mouse-protection tests against challenge with M24 but not M6 streptococci. None of the volunteers developed heart-reactive antibodies or antibodies to non-type-specific M protein antigens. Alum-precipitated pep M24 was well-tolerated in man, and no serious local or systemic reactions were observed. Thus, pep M24 induces type-specific, protective antibodies in doses that are well-tolerated in man.

Citing Articles

Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.

Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M Cureus. 2023; 14(12):e33146.

PMID: 36721580 PMC: 9884514. DOI: 10.7759/cureus.33146.


Correlates of immunity to Group A Streptococcus: a pathway to vaccine development.

Frost H, Excler J, Sriskandan S, Fulurija A NPJ Vaccines. 2023; 8(1):1.

PMID: 36650164 PMC: 9844947. DOI: 10.1038/s41541-022-00593-8.


Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.

Spencer J, Penfound T, Salehi S, Aranha M, Wade L, Agarwal R Vaccine. 2021; 39(12):1773-1779.

PMID: 33642159 PMC: 8045747. DOI: 10.1016/j.vaccine.2021.01.075.


Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.

Fischetti V Microbiol Spectr. 2019; 7(3).

PMID: 31111819 PMC: 11026073. DOI: 10.1128/microbiolspec.GPP3-0010-2018.


Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Bronze M, Dale J Am J Med Sci. 2010; 340(3):218-25.

PMID: 20697258 PMC: 2935929. DOI: 10.1097/MAJ.0b013e3181e939ab.


References
1.
Fischetti V . Streptococcal M protein extracted by nonionic detergent. II. Analysis of the antibody response to the multiple antigenic determinants of the M-protein molecule. J Exp Med. 1977; 146(4):1108-23. PMC: 2180815. DOI: 10.1084/jem.146.4.1108. View

2.
Beachey E, Seyer J, Kang A . Repeating covalent structure of streptococcal M protein. Proc Natl Acad Sci U S A. 1978; 75(7):3163-7. PMC: 392734. DOI: 10.1073/pnas.75.7.3163. View

3.
Beachey E, STOLLERMAN G, Chiang E, Chiang T, Seyer J, Kang A . Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen. J Exp Med. 1977; 145(6):1469-83. PMC: 2180682. DOI: 10.1084/jem.145.6.1469. View

4.
van de Rijn I, Zabriskie J, McCarty M . Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen. J Exp Med. 1977; 146(2):579-99. PMC: 2180771. DOI: 10.1084/jem.146.2.579. View

5.
Beachey E, Chiang E, Seyer J, Kang A, Chiang T, STOLLERMAN G . Separation of the type specific M protein from toxic cross reactive antigens of group A streptococci. Trans Assoc Am Physicians. 1977; 90:390-400. View